11results about How to "Improve lesion" patented technology

The invention relates to the technical field of biological medicine, in particular to radix puerariae and sesame coffee for improving non-alcoholic fatty liver and application of the radix puerariae and sesame coffee. The radix puerariae and sesame coffee comprises the following components in parts by weight: 0.5 part of a fructus cannabis polypeptide solution, 0.5 part of radix puerariae polypeptide solution and 9 parts of coffee. After continuous treatment for 7 weeks, according to liver appearance and liver histopathology observation, it is found that the radix puerariae and sesame coffee mixed liquid effectively reduces lipid deposition and liver fat, and the liver fat lesion is improved. Experimental results show that the radix puerariae and hemp coffee has a remarkable lipid-lowering effect, and can effectively reduce liver fat particles, reduce inflammatory injury, improve liver tissue pathological changes and relieve NAFLD mouse liver tissue injury.

This invention belongs to the field of biomedical technology, specifically disclosing the use of FOXO1 in the prevention and treatment of calcific aortic valve disease. It mainly involves the application of FOXO1 or its expression-promoting agents in the prevention and treatment of calcific aortic valve disease, and the application of FOXO1 in the preparation of animal models of calcific aortic valve disease. This invention increases or maintains FOXO1 expression to maintain the binding of FOXO1 to Runx2, and further maintains the normal valvular mechanism levels, thereby preventing and alleviating the occurrence of calcific aortic valve disease. Simultaneously, this invention also provides a new animal model for the study of calcific aortic valve disease, facilitating subsequent research on this condition.

The invention relates to the technical field of biology, and particularly discloses clostridium praeparatum capable of improving metabolism-related steatohepatitis and application of the clostridium praeparatum. The clostridium pralaense is Faecalibacteria pralausnitziiGZSY3214, the clostridium pralaense is preserved in the Guangdong Microbial Culture Collection Center on August 7, 2024, and the preservation number of the clostridium pralaense is GDMCC (China General Microbiological Culture Collection Center) No: 64992. The clostridium pralaense has been preserved in the Guangdong Microbial Culture Collection Center on August 7, 2024. After being treated by the clostridium pralaense, the clostridium pralaense has a good curative effect on improving the progress of metabolism-related steatohepatitis diseases, and has a remarkable inhibition effect on NF-kB and MAPK signal pathways, participating in inflammatory reaction, of the liver; wherein the strain can also improve liver function and lipid metabolism, down-regulate contents of ALT, AST, TG, LDL and the like, inhibit expression of inflammation-related inflammatory cytokines and chemotactic factors, and significantly inhibit expression of liver fibrosis-related collagen and transforming growth factor-beta.

The application belongs to the technical field of biological medicine, and specifically discloses application of jatrorrhizine in preparation of a medicine for preventing and treating intestinal radiation injury, and a medicine for preventing and treating intestinal radiation injury.The application verifies the effect of jatrorrhizine on resisting intestinal radiation injury by using an intestinal organ model, wherein the jatrorrhizine can obviously improve the changes in survival rate, bud number and organ size of the intestinal organ caused by radiation injury, and eliminate the adverse effects caused by the intestinal radiation injury.After abdominal irradiation injury of experimental mice, jatrorrhizine is injected into the abdominal cavity, the intestinal length is obviously increased, the survival rate is improved, and HE staining of small intestinal sections shows that the crypt depth and villus structure are improved.It is proved that the jatrorrhizine can promote the regeneration and repair of the intestinal organ after radiation, improve the survival rate, and improve the morphological changes of the intestinal caused by radiation injury.The medicine containing the jatrorrhizine provided by the application can improve the intestinal lesions caused by radiation injury, relieve the intestinal injury symptoms, and improve the survival rate of individuals.

The strength of a tube having a lumen in a catheter is improved. The catheter comprises a first tube having a first lumen, and a second tube having a second lumen. The first tube has an inner layer corresponding to the innermost layer of the first lumen, an outer layer surrounding the inner layer, and a reinforcing layer sandwiched between the inner layer and the outer layer.

The invention relates to the technical field of biology, and particularly discloses a Prevotella bivia strain and application of the Prevotella bivia strain in preparation of a product for improving metabolism-related fatty liver diseases. The Prevotella bivia strain adopted by the invention has a good curative effect on the metabolism-related fatty liver disease, and has a remarkable inhibition effect on the liver participating in inflammatory reaction, and the inhibition effect is specifically shown as reduction of inflammatory factors such as ALT, AST, TG, CHO and LDL; according to the application, the treatment effect of the Prevotella bivia strain in the metabolism-related fatty liver disease is defined, so that an effective medicine for clinically treating the metabolism-related fatty liver disease is provided, and the Prevotella bivia strain has a relatively good application prospect.

The invention discloses application of surfactin family lipopeptide in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the field of biological medicine. Experiments prove that the surfactin family lipopeptide can significantly reduce weight gain and liver weight of a model mouse, reduce the ratio of liver weight to weight, relieve HFD-induced hepatic distension and lipid droplet accumulation, improve hepatic lesion, and reduce the liver weight of the model mouse. In addition, according to verification of the invention, single surfactin A, surfactin B or surfactin C can also play a role in improving NAFLD (non-alcoholic fatty liver disease) of mice induced by high fat diet. The significant effect and transformation potential of the surfactin family lipopeptide in prevention and treatment of the non-alcoholic fatty liver are verified, so that the surfactin family lipopeptide can be applied to preparation of drugs for prevention and treatment of the non-alcoholic fatty liver, and a new thought is provided for clinical treatment of prevention and treatment of the non-alcoholic fatty liver.

The invention discloses a method for researching the relation between intestinal colonization and oviduct edema after chlamydia genital tract infection and application, and belongs to the technical field of biological medicine. The invention provides a complete and standardized research system which can be used for researching the relationship between intestinal colonization and oviduct edema after chlamydia genital tract infection; the provided method reveals for the first time that chlamydia genital tract infection is colonized in intestinal tracts and has an inevitable relation with the formation of lasting and stable oedema of fallopian tubes, and a new direction is provided for prevention and treatment of oedema of fallopian tubes induced by chlamydia genital tract infection; therefore, the method provided by the invention can be used for researching the relationship between chlamydia intestinal colonization and oviduct edema, and also has a reference value for other similar researches; the invention also provides a group of preparations which can be used for diagnosis and / or risk prediction and / or prevention and / or treatment of fallopian tube edema induced by chlamydia genital tract infection, and the preparations are symbolic flora obtained by identification with the method provided by the invention.

The present invention belongs to the field of medicine and relates to the medical use of Patchouli leaf extract. Specifically, the present invention relates to the use of Patchouli leaf extract in the preparation of anti-influenza drugs. Patchouli leaf extract has a significant anti-influenza virus effect, low cytotoxicity, and good application prospects.

The application provides a kind of fermentation composition for assisting relieving asthenopia and its preparation method and application, belong to composition technical field.The fermentation composition is composed of the following components by weight:chrysanthemum 10-20 parts, medlar 10-20 parts, wine rhizoma polygonati 5-15 parts, radix codonopsitis 10-20 parts, fried cassia seed 5-10 parts and rose flower 5-10 parts.The application adopts the treatment method of "moistening water and nourishing yin, soothing liver and improving eyesight", and uses chrysanthemum, medlar, wine rhizoma polygonati, radix codonopsitis, fried cassia seed and rose flower, six kinds of food-medicine homologous traditional Chinese medicines for relieving asthenopia have good curative effect.

The present application provides use of Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof in manufacture of a medicament useful in treating a disease related to high expression or abnormal activation of JAK and SYK kinases, comprising an autoimmune disease, such as an immune-mediated skin disease, in particular psoriasis, atopic dermatitis and SLE. Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention can improve the skin lesions in mice with psoriasis, atopic dermatitis and SLE, alleviate the injury of kidney, inhibit the expansion of immune organs, reduce the level of inflammation, inhibit the increase of SLE related antibodies and cytokines in serum, and has a certain safe therapeutic window, which has a good clinical application prospect.